Basilar trunk artery aneurysms are a rare and serious type of brain aneurysm with limited treatment data. A study finds that most patients can be successfully treated using minimally invasive procedures, with nearly nine in ten achieving good recovery. Based on one of the largest single-center analyses to date, this study highlights the effectiveness of modern endovascular techniques while pointing to higher risks in larger aneurysms, emphasizing the need for careful patient selection and follow-up.

Researchers from the SABIEN group at the ITACA Institute of the Universitat Politècnica de València (UPV), in collaboration with several partner institutions, have developed a new tool to estimate the risk of using medicines while driving.

The research, led by Vicente Traver and Salvador Borja and published in the scientific journal Therapeutic Advances in Drug Safety, introduces the FMB scale (Mobility and Risk Basis Factor) — a continuous, multifactorial model that enhances the traditional evaluation based on the DRUID system (Driving under the Influence of Drugs, Alcohol and Medicines), currently the most widely used reference in Europe.

Dear Experts and Colleagues,

    We are pleased to invite you to present and participate in our first annual Experimental Therapeutics at Ruijin meeting, to be held on June 1st to 4th,  2026, at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Annual meeting will bring together leading investigators to share experiences in translating scientific discoveries into clinical success. We hope the event will provide every participant—faculty, students, and guests alike—with valuable insights and a stimulating exchange of ideas. The organizers are:

    H. Michael Shepard, PhD – Experimental Therapeutics Group, Ruijin Hospital, Shanghai

    Baiyong Shen, MD – Professor and Chief Physician, Ruijin Hospital, Shanghai

    Mone Zaidi, PhD – Icahn School of Medicine at Mount Sinai, New York

    We anticipate a high level of interest in this topic and will provide ample opportunity for meaningful interaction and discussion among participants. Some presentations will highlight programs with regulatory approval, while most will focus on those with preclinical or early clinical proof of concept.

    We sincerely hope you can join us for this exciting event in Shanghai.

    Time: June 1st to 4th, 2026

    Location: 1F Lecture Hall, Building 35, Translational Medicine Building, No. 197 Ruijin 2nd Road, Ruijin Hospital, Shanghai, China

    Contact: ying.zhang@jueqianmed.com